Glimeripide insulin secretagogues
Description Results

hydroxy-glimepiride - Amarel, hydroxyglimepiride - Amaryl - Roname - HOE-490 - HOE 490 - glymepiride - glimepiride

pdf

pathology

Benefit (demonstrated or suggested) and harm

diabetes type 2

All results are NS for efficacy

Trial	control	p<0.05	harm	NS
LEAD-2 (Nauck) Sulf vs pbo, 2009	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
Charpentier, 2001	vs placebo (add on MET)			CV death 1.00 [0.38; 2.62] All-cause mortality 1.00 [0.38; 2.62] Stroke 1.00 [0.38; 2.62] Myocardial infarction 1.00 [0.38; 2.62]
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)
	vs placebo (add on MET)

Trial	Treatments	Patients	Method
LEAD-2 (Nauck) Sulf vs pbo, 2009	glimepiride (4 mg once daily). (n=-9) vs. placebo (n=-9)	subjects previously treated with oral antidiabetes (OAD) therapy	double-blind Sample size: -9/-9 Primary endpoint: FU duration: 26 weeks
Draeger, 1996	glimepiride 1 mg daily (n=524) vs. 2.5 mg glibenclamide (n=520)	type 2 diabetic patients stabilised on glibenclamide	double-blind Parallel groups Sample size: 524/520 Primary endpoint: not unique FU duration:
Dills, 1996	glimepiride 1-16mg od (n=289) vs. non-micronized glyburide 1.25-20mg od (n=288)	patients with non-insulin dependent diabetes	double-blind Parallel groups Sample size: 289/288 Primary endpoint: FU duration:
Inukai, 2005	glimepiride (n=172) vs. gliclazide or glibenclamide (n=0)	Japanese type 2 diabetic patients (HbA1C > or = 7.0%), maintained on a conventional SU	open Parallel groups Sample size: 172/0 Primary endpoint: FU duration: 6 months
Study 201 (Goldberg), 1996	glimepiride, 1, 4, or 8 mg once daily (n=304) vs. placebo (n=0)	patients with NIDDM	double-blind Parallel groups Sample size: 304/0 Primary endpoint: FU duration: 14 weeks
Schade, 1998	glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks (n=123) vs. placebo (n=126)	patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful	double-blind Parallel groups Sample size: 123/126 Primary endpoint: FU duration:
Rosenstock, 1996	glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d (n=416) vs. placebo (n=0)	previously treated NIDDM patients	double-blind Parallel groups Sample size: 416/0 Primary endpoint: FU duration: 14 weeks
Luis Bautista, 2003	glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL (n=-9) vs. placebo (n=-9)	Mexican American Patients with type 2 diabetes mellitus	double-blind Parallel groups Sample size: -9/-9 Primary endpoint: change in HbA(1c) FU duration: 14 weeks
Charpentier, 2001	metformin and glimepiride (n=-9) vs. metformin (n=-9) metformin, glimepiride or metformin and glimepiride	Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily	double-blind Sample size: -9/-9 Primary endpoint: FU duration:
Protocol 311	glimepiride 1-8mg od (n=427) vs. glibenclamide 1.75-14 mg/day (od or bid) (n=425)		Sample size: 427/425 Primary endpoint: FU duration:
Clark (301), 1997	glimepiride 1-16 mg/day (od or bid) (n=444) vs. glipizide 2.5-40 mg/day (od or bid) (n=208)		Sample size: 444/208 Primary endpoint: FU duration:
Kaneko, 1993	glimepiride 0.25mg od, 0.5mg od (n=62) vs. placebo (n=31)		Sample size: 62/31 Primary endpoint: FU duration:
Study 202	glimepiride 1-8mg od (n=122) vs. placebo (n=125)		Sample size: 122/125 Primary endpoint: FU duration:
Sonnenberg, 1997	glimepirid e6mg od (n=50) vs. glimepiride 3mg bid (n=48)		Cross over Sample size: 50/48 Primary endpoint: FU duration:
Charpentier (301F)	glimepiride 1-4mg od (n=96) vs. gliclazide 80-320 mg/day (od or bid) (n=107)		Sample size: 96/107 Primary endpoint: FU duration:
Riddle, 1994	Glimepiride (16 mg/day) plus insulin (n=72) vs. insulin plus placebo (n=73)	obese patients with type 2 diabetes insufficiently controlled by full dosages of sulphonylureas (glimepiride titrated up to 8mg twice daily and with laboratory-monitored FPG of 10 to 16 mmol/L (180 to 300 mg/dl))	Sample size: 72/73 Primary endpoint: FU duration: